CN112998275A - Ready-to-eat probiotic composition - Google Patents

Ready-to-eat probiotic composition Download PDF

Info

Publication number
CN112998275A
CN112998275A CN201911326592.5A CN201911326592A CN112998275A CN 112998275 A CN112998275 A CN 112998275A CN 201911326592 A CN201911326592 A CN 201911326592A CN 112998275 A CN112998275 A CN 112998275A
Authority
CN
China
Prior art keywords
probiotic
eat
ready
probiotic composition
probiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911326592.5A
Other languages
Chinese (zh)
Inventor
白树民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Shengshi Yibei Medical Instrument Co ltd
Original Assignee
Guangzhou Shengshi Yibei Medical Instrument Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Shengshi Yibei Medical Instrument Co ltd filed Critical Guangzhou Shengshi Yibei Medical Instrument Co ltd
Priority to CN201911326592.5A priority Critical patent/CN112998275A/en
Publication of CN112998275A publication Critical patent/CN112998275A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/517—Bifidum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention relates to an instant probiotic composition, and solves the technical problems that the cell wall of probiotic is broken due to the force and temperature of a tablet press during tabletting of the probiotic composition in the prior art, the survival rate of the probiotic is low, the efficacy of the probiotic is reduced, and the stability of the probiotic in the storage process is poor. The invention provides a ready-to-eat probiotic composition, which comprises probiotics, sugar alcohol, oligoxylitol, tricalcium phosphate and acerola powder; the probiotic bacteria comprise Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus. The invention is widely applied to the technical field of health-care food.

Description

Ready-to-eat probiotic composition
Technical Field
The invention relates to the technical field of health-care food, in particular to an instant probiotic composition.
Background
Immunity is the body's own defense mechanism, is the body's ability to resist external invasion, maintain the stability of the body's environment, and is the body's ability to recognize and eliminate any foreign body (virus, bacteria, etc.) invaded from the outside, to treat aged, damaged, dead, denatured self-cells, and to recognize and treat mutant cells and virus-infected cells in the body. When the human body has immune dysfunction or the immune system is not healthy, the body is easy to be infected, such as cold, tonsillitis, asthma, bronchitis, pneumonia, diarrhea and other repeated attacks, and serious diseases, such as cancer, are also easy to be induced. Modern medical science finds that immunity is a factor closely related to aging. According to related reports, the immunity function of the organism begins to be delayed when the organism is about 30 years old, and the number of people with low immunity tends to increase year by year due to factors such as rapid change of activities, irregular life, pressure of working and learning environments, lack of exercise and the like of modern life. Therefore, how to improve the immunity of people with low immunity becomes a hot spot of modern medical research.
Probiotics is a kind of active microorganisms beneficial to a host, and is a general term for active beneficial microorganisms which are planted in the intestinal tract and the reproductive system of a human body and can generate definite health efficacy so as to improve the micro-ecological balance of the host and play beneficial roles. The probiotic bacteria can enhance immunity, and can regulate too low or too high immunological activity to normal state by stimulating the immune function in intestinal tract. This immunomodulatory effect of probiotics is also thought to contribute to cancer resistance and inhibition of allergic diseases. Probiotics are "living microorganisms that, when administered in the correct amount, confer a health benefit to the host". Probiotics have been described in species belonging to the genera Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium), Streptococcus (Streptococcus) and Lactococcus (Lactococcus) commonly used in the dairy industry. It is believed that probiotics intervene at the level of the intestinal flora by hindering the growth of pathogenic microorganisms and/or by acting more directly on the immune system.
The probiotic chewable tablet is prepared by preparing probiotic into powder, can enhance intestinal immune barrier function, relieve the penetration of pathogenic bacteria to mucous membrane, and help to enhance the physique of children and adults, and is convenient to take and good in compliance. However, the existing probiotic chewable tablets have low survival rate and low efficacy because the cell walls of the probiotics are broken by the force and the temperature of a tablet press during tabletting. Therefore, there is a need to provide a chewable tablet with a high survival rate of probiotics.
The gastrointestinal tract of a healthy person is populated by a wide variety of microorganisms, which are referred to as intestinal flora. The intestinal flora is combined according to a certain proportion, the bacteria are restricted and dependent with each other, an ecological balance is formed on the quality and quantity, once the internal and external environments of the organism change, the flora imbalance is caused, the normal physiological combination of the organism is destroyed, the pathological combination is generated, and the clinical symptoms are called the intestinal flora imbalance.
The amount of intestinal probiotics has become one of the criteria for testing the health of a human body. The physiological action of the medicine on human bodies is shown as follows: antibacterial property, which is to decompose organic acid in intestinal tract to reduce acidity of intestinal tract and inhibit putrefying bacteria; supplying vitamins to human body, generating various vitamins by probiotics, and inhibiting the decomposition of certain substances to ensure the supply; enhancing immunity, stimulating intestinal immune cells, and improving immunity. However, in daily life, the deterioration of environment and unhealthy life style are accompanied by the increase of life pressure, more and more people generate emotions such as anxiety, depression and the like due to excessive mental stress to cause dysfunction of neuroendocrine system, most of sensitive bacteria and normal flora can be inhibited or killed after the modern society uses a large amount of broad-spectrum antibiotics for a long time, while drug-resistant bacteria breed a large amount due to the selection function of the antibiotics, and the factors can cause physiological dysfunction of intestinal tracts, unbalance the micro-ecological environment in the intestinal tracts and further cause the aging of the intestinal tracts.
Chinese patent publication CN106659747A discloses the use of lactobacillus rhamnosus for promoting recovery of intestinal flora diversity after dysbiosis: by formulating lactobacillus rhamnosus in a form that can be administered orally for maintaining or increasing the intestinal flora diversity in a subject, for alleviating intestinal dysbiosis in a subject caused by antibiotics, for preventing intestinal bacterial infections and/or the development of diseases caused by pathogenic bacteria in the intestinal tract of a subject. However, the oral preparation containing probiotics prepared in the patent has few types of probiotics, cannot fully exert the synergistic effect among various probiotics, and does not fully consider the problems of survival rate and stability of the probiotics in the storage process in the preparation process.
Chinese patent publication CN106072657A discloses a probiotic composition and a preparation method thereof, wherein the probiotic composition is mainly prepared from the following substances in percentage by weight: 1-3% of lactobacillus acidophilus powder, 0.5-1.5% of lactobacillus casei powder, 1-3% of bifidobacterium lactis powder, 5-8% of mannan oligosaccharide, 3-5% of plantain seed powder, 40-60% of fructo-oligosaccharide, 2-5% of corn oligopeptide powder, 3-5% of inulin, 5-8% of blueberry powder and 10-25% of maltodextrin. The prepared probiotic composition can not only effectively regulate intestinal flora, but also enhance the immunity of human bodies. The invention does not carefully study the specific effects of various probiotic compositions on the diversity of the intestinal flora and still does not concern the stability of the probiotic compositions during storage.
Therefore, there is a need for an efficient large-scale production method of lactobacillus acidophilus; there is a need for an oral probiotic formulation that is shelf stable and that simultaneously contains multiple probiotics and is capable of improving the diversity of the intestinal flora.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the ready-to-eat probiotic composition which is simple and reasonable in raw material composition, scientific in compatibility, synergistic, high in survival rate of probiotics in probiotic powder, high in survival rate in a tabletting process and convenient to take.
The technical scheme adopted by the invention for solving the technical problem is as follows: the invention provides a ready-to-eat probiotic composition, which comprises probiotics, sugar alcohol, oligoxylitol, tricalcium phosphate and acerola powder; the probiotic bacteria comprise Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus.
Preferably, the ratio of the probiotics, the sugar alcohol, the xylitol oligomer, the tricalcium phosphate and the acerola cherry powder is as follows in parts by weight: the probiotics comprise lactitol, oligoxylitol, tricalcium phosphate, acerola cherry powder = (40-50), (40-90), (2-6), (2-4) and (1-10).
Preferably, the ratio of the probiotics in the probiotics is bifidobacterium bifidum, bifidobacterium lactis, bifidobacterium longum, lactobacillus acidophilus, lactobacillus rhamnosus = (10-20): (5-10): 1-5): 1-2 in parts by weight.
Preferably, the sugar alcohol has a pore volume of 0.005 to 0.05cm3A specific surface area of 1-10 cm3/g。
Preferably, the sugar alcohol is one or more of sorbitol, maltitol, mannitol, lactitol, erythritol, isomalt and xylitol.
Preferably, it further comprises prebiotics and/or dietetically acceptable adjuvants.
Preferably, the formulation of the ready-to-eat probiotic composition is composite probiotic freeze-dried powder; the composite probiotic freeze-dried powder is obtained by carrying out vacuum freeze-drying on bacterial liquid.
The invention has the beneficial effects that:
(1) the invention has scientific compatibility and synergistic interaction, ensures that the probiotic powder has high survival rate of the probiotics, high survival rate and high viable count in the tabletting process, increases the viable count of the probiotics cultured independently while ensuring the respective health-care effect, and embodies the unique superiority of the formula. . Compared with the commercial probiotic freeze-dried powder product, the compound probiotic composition formula obtains a special strain quantity ratio through research, so that the quantity of the bacteria planted in the intestinal tract is optimized. After being prepared into the enteric composite probiotic freeze-dried powder capsule, the capsule can be used for supplementing probiotics required by human bodies and balancing intestinal flora balance, is beneficial to preventing and treating certain diseases from bacteria, viruses, fungi and protozoa, and also has the effects of removing harmful substances, eliminating in-vivo toxins, purifying in-vivo environment and the like.
(2) The probiotic chewable tablet has the advantages of high particle porosity, large specific surface area, good compressibility and high hardness yield; the product is convenient to eat and has good taste; the storage time is long.
Detailed Description
The present invention will be further described with reference to specific examples to assist understanding of the invention. The method used in the invention is a conventional production method if no special provisions are made; the starting materials used, unless otherwise specified, are conventional commercial products.
Example 1
A ready-to-eat probiotic composition comprising probiotic bacteria, lactitol, oligolactitol, tricalcium phosphate and acerola powder; the probiotic bacteria comprise Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus; the probiotics comprise, by weight, lactitol, oligoxylitol, tricalcium phosphate and acerola cherry powder =40:40:2:4: 10; bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus rhamnosus =10:10:5:1: 1. The pore volume of the sugar alcohol is 0.005-0.05 cm3A specific surface area of 1-10 cm3/g。
The formulation of the ready-to-eat probiotic composition is composite probiotic freeze-dried powder; the composite probiotic freeze-dried powder is obtained by carrying out vacuum freeze-drying on bacterial liquid.
The damage to the structure and the characteristics of biological tissues and cells is small by adopting a vacuum freeze-drying technology, so that the biological tissues and the cell structures can rapidly enter a dormant state, and the stability of active ingredients of a plurality of heat-sensitive products such as probiotics is effectively protected. The invention also provides application of the composite probiotic freeze-dried powder capsule in health-care food for regulating intestinal functions.
Example 2
A ready-to-eat probiotic composition comprising probiotic bacteria, lactitol, oligolactitol, tricalcium phosphate and acerola powder; the probiotic bacteria comprise Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus; the probiotic comprises, by weight, lactitol, oligoxylitol, tricalcium phosphate and acerola cherry powder =50:90:6:2: 1; bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus rhamnosus =20:20:10:1: 2. The pore volume of the sugar alcohol is 0.005-0.05 cm3A specific surface area of 1-10 cm3/g。
The formulation of the ready-to-eat probiotic composition is composite probiotic freeze-dried powder; the composite probiotic freeze-dried powder is obtained by carrying out vacuum freeze-drying on bacterial liquid.
The damage to the structure and the characteristics of biological tissues and cells is small by adopting a vacuum freeze-drying technology, so that the biological tissues and the cell structures can rapidly enter a dormant state, and the stability of active ingredients of a plurality of heat-sensitive products such as probiotics is effectively protected. The invention also provides application of the composite probiotic freeze-dried powder capsule in health-care food for regulating intestinal functions.
Example 3
A ready-to-eat probiotic composition comprising probiotic bacteria, lactitol, oligolactitol, tricalcium phosphate and acerola powder; the probiotic bacteria comprise Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus; the probiotic comprises, by weight, lactitol, oligoxylitol, tricalcium phosphate and acerola cherry powder =45:80:5:3: 1; bifidobacterium bifidum, bifidobacterium lactis, bifidobacterium longum, lactobacillus acidophilus and lactobacillus rhamnosus =15:15:7:3: 1. The pore volume of the sugar alcohol is 0.005-0.05 cm3Table of the ratio of/gThe area is 1-10 cm3/g。
The formulation of the ready-to-eat probiotic composition is composite probiotic freeze-dried powder; the composite probiotic freeze-dried powder is obtained by carrying out vacuum freeze-drying on bacterial liquid.
The damage to the structure and the characteristics of biological tissues and cells is small by adopting a vacuum freeze-drying technology, so that the biological tissues and the cell structures can rapidly enter a dormant state, and the stability of active ingredients of a plurality of heat-sensitive products such as probiotics is effectively protected. The invention also provides application of the composite probiotic freeze-dried powder capsule in health-care food for regulating intestinal functions.
The efficacy of the ready-to-eat probiotic composition of the present invention is further illustrated by the experimental reports below.
1. Object and method
(1) The test substance: ready-to-eat probiotic compositions prepared according to the formulations given in examples 1 to 3 of the present invention were experimental samples.
(2) The method for measuring the abundance of the flora comprises the following steps: taking 110 mice with good and same growth state, randomly dividing the mice into 5 groups, each group comprising 20 mice, wherein 3 groups are experimental groups, 2 groups are control groups, uniformly feeding the mice under the same environment, and after feeding the mice for one week, carrying out continuous 7-day intragastric gavage on the mice, wherein the experimental groups adopt the composition of the embodiments 1-3 of the invention to carry out intragastric gavage. After the gastric lavage is finished for 7 days, collecting a fecal sample of the mouse, and using the fecal sample for the investigation and analysis of the 16SrRNA gene of the whole flora to detect the abundance of the flora in the mouse.
(3) The survival rate of the probiotics in the ready-to-eat probiotic composition refers to the survival rate of the ready-to-eat probiotic composition after the ready-to-eat probiotic composition is placed at 25 ℃ for 4 months.
The experimental result shows that the ready-to-eat probiotic composition can improve the abundance of the flora in mice from 400 to 448 and reduce the lgCFU/g value of enterococcus from 6.8 to below 6.0 by adding various probiotics into the composition, and has the obvious effects of improving the diversity of intestinal flora and reducing the content of harmful bacteria. When the addition of certain probiotics is omitted from the composition, the efficacy of the composition in increasing the abundance of the intestinal flora and in reducing the content of harmful bacteria may be reduced to different extents.
In conclusion, the experimental data results fully prove that the ready-to-eat probiotic composition has scientific compatibility and synergistic interaction, so that the survival rate of probiotics in the probiotic powder is high, and the survival rate and the viable count in the tabletting process are high; the product is convenient to eat and has good taste; the storage time is long.
However, the above description is only an embodiment of the present invention, and the scope of the present invention should not be limited by this, and all equivalent changes and modifications made in the claims of the present invention should be covered by the present invention.

Claims (7)

1. A ready-to-eat probiotic composition comprising probiotics, sugar alcohol, xylitol oligosaccharide, tricalcium phosphate and acerola powder; the probiotic bacteria comprise Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus.
2. The ready-to-eat probiotic composition according to claim 1, wherein the ratio of the probiotics to the sugar alcohol, the xylitol oligosaccharide, the tricalcium phosphate and the acerola powder is as follows: the probiotics comprise lactitol, oligoxylitol, tricalcium phosphate, acerola cherry powder = (40-50), (40-90), (2-6), (2-4) and (1-10).
3. The ready-to-eat probiotic composition according to claim 2, wherein the ratio of the probiotics in the probiotic composition is Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus = (10-20): 5-10): 1-5): 1-2.
4. A ready-to-eat probiotic composition according to claim 1 or 2, characterized in that said sugar alcohol has a pore volume of 0.005-0.05 cm3A specific surface area of 1-10 cm3/g。
5. The ready-to-eat probiotic composition according to claim 1, characterized in that said sugar alcohol is one or more of sorbitol, maltitol, mannitol, lactitol, erythritol, isomalt, xylitol.
6. A ready-to-eat probiotic composition according to claim 1, characterized in that it also comprises prebiotics and/or dietetically acceptable adjuvants.
7. The ready-to-eat probiotic composition according to claim 6, wherein the ready-to-eat probiotic composition is in the form of composite probiotic freeze-dried powder; the composite probiotic freeze-dried powder is obtained by carrying out vacuum freeze-drying on bacterial liquid.
CN201911326592.5A 2019-12-20 2019-12-20 Ready-to-eat probiotic composition Pending CN112998275A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911326592.5A CN112998275A (en) 2019-12-20 2019-12-20 Ready-to-eat probiotic composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911326592.5A CN112998275A (en) 2019-12-20 2019-12-20 Ready-to-eat probiotic composition

Publications (1)

Publication Number Publication Date
CN112998275A true CN112998275A (en) 2021-06-22

Family

ID=76382699

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911326592.5A Pending CN112998275A (en) 2019-12-20 2019-12-20 Ready-to-eat probiotic composition

Country Status (1)

Country Link
CN (1) CN112998275A (en)

Similar Documents

Publication Publication Date Title
CN102905712B (en) Be used for the treatment of the probiotic composition of enteritis
JP2015512936A (en) Prebiotic composition and method of use thereof
AU2014291777B2 (en) A composition having a prebiotic effect
CN1480528A (en) Bifidobacterium and products contg same
KR101104397B1 (en) Antiviral composition of fermented milk from lactic bacteria and its therof
CN111528479A (en) Probiotics and prebiotics composition for relieving atopic dermatitis function and application
EP3781185B1 (en) Method for alleviating tobacco or nicotine withdrawal symptoms
KR20210112342A (en) Strain, composition and method of use
US20130309212A1 (en) Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition
CN107854495B (en) Application of bacillus coagulans in preparation of preparation for reducing hematuria
JP2018532380A (en) Enterobacteriaceae butyric acid intestini and uses thereof
WO2015140299A1 (en) Oronasopharyngeal probiotics
WO2019227414A1 (en) Composition and uses thereof
CN109414465B (en) Probiotic compositions and uses thereof
KR101849424B1 (en) Use of a fermented soy extract for manufacture of a prebiotic composition
CN112998275A (en) Ready-to-eat probiotic composition
CN116396884A (en) Lactobacillus rhamnosus and a composition for inhibiting helicobacter pylori
KR102480131B1 (en) Lactobacillus rhamnosus with cognitive function improvement
KR102480136B1 (en) Lactobacillus paracasei with cognitive function improvement
EP3691665B1 (en) A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections
CN111560335A (en) Bifidobacterium lactis for relieving asthma and application thereof
WO2019227417A1 (en) Composition and uses thereof
US20240050493A1 (en) Strains, compositions and methods of use
KR102685867B1 (en) Pharmaceutical composition for preventing or treating the acquisition of drug-resistant infections comprising a combination of probiotics and prebiotics
EP1900371A1 (en) Method for treating and/or preventing intestinal bacterial imbalance

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210622